Evotec SE (EVO)

Market Cap	1.07B
Revenue (ttm)	887.40M
Net Income (ttm)	-186.53M
Shares Out	177.67M
EPS (ttm)	-1.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,413
Open	3.000
Previous Close	3.080
Day's Range	2.970 - 3.035
52-Week Range	2.840 - 5.641
Beta	1.15
Analysts	Strong Buy
Price Target	7.00 (+133.72%)
Earnings Date	Nov 5, 2025

About EVO

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic disease...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 4, 2021
• Employees: 4,740
• Stock Exchange: NASDAQ
• Ticker Symbol: EVO
• Website: https://www.evotec.com

Financial Performance

In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.

Financial numbers in EUR

Analyst Summary

According to one analyst, the rating for EVO stock is "Strong Buy" and the 12-month stock price target is $7.0.

Price Target

$7.0

(133.72% upside)

Analyst Consensus: Strong Buy